Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Nov;27(47):2101133.
doi: 10.2807/1560-7917.ES.2022.27.47.2101133.

Rotavirus epidemiology and genotype distribution in hospitalised children, Greece, 2008 to 2020: A prospective multicentre study

Affiliations
Multicenter Study

Rotavirus epidemiology and genotype distribution in hospitalised children, Greece, 2008 to 2020: A prospective multicentre study

Dimitra-Maria Koukou et al. Euro Surveill. 2022 Nov.

Abstract

BackgroundTwo rotavirus (RV) vaccines were licensed in Greece in late 2006 and included in the national immunisation programme in 2012.AimTo study the epidemiology and genotype distribution of RV in children during the post-vaccination period and assess the impact of increased vaccination coverage.MethodsIn a prospective multicentre hospital-based study, hospitalised children (≤ 16 years) with an RV-positive faecal sample were recruited. Epidemiological and genotyping analyses were performed; periods of low (2008-12) and moderate (2012-20) RV vaccination coverage were compared. Statistical analysis was performed with a chi-squared or Mann-Whitney U test and logistic regression.ResultsA total of 3,874 children (55.6% male; n = 2,153) with median age of 1.4 years (IQR: 0.5-3.3) were studied during 2008-20. Most RV-infected children were aged ≤ 3 years (72.2%) and hospitalised during December-May (69.1%). Common RV genotypes (G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], G12P[8]) were detected in 92.2% of samples; G-P combinations with prevalence above 1% were G4P[8] (44.1%), G1P[8] (25.4%), G2P[4] (14.9%), G9P[8] (3.5%), G12P[8] (2.2%), G3P[8] (2.1%), other (4.3%) and mixed (3.5%). Of all samples, 97.6% were homotypic or partially heterotypic to vaccines' genotypes. With moderate vaccination coverage, the seasonal peak was detected earlier, children were older and partially or fully heterotypic genotypes were increased (p < 0.001).ConclusionsIn the era of moderate RV vaccination coverage in Greece, epidemiology of RV in hospitalised children seemed to change. However, most circulating genotypes remain homotypic or partially heterotypic to RV vaccines. Continuous epidemiological surveillance and genotyping are important to monitor possible changes arising from RV vaccines' implementation.

Keywords: Greece; Rotavirus; children; gastroenteritis; genotypes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: GT is an employee of MSD Greece which holds the market authorisation of Rotavirus vaccine RotaTeq®. All the other authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Monthly distribution of children aged ≤ 16 years hospitalised with rotavirus gastroenteritis during the post-rotavirus vaccination period, Greece, 2008–2020 (n = 3,874)
Figure 2
Figure 2
Annual distribution of rotavirus genotypes circulating in children aged ≤ 16 years hospitalised with rotavirus gastroenteritis during the post-rotavirus vaccination period, Greece, 2008–2020 (n = 3,346)

References

    1. Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Reiner RC, Jr, et al. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(9):909-48. 10.1016/S1473-3099(17)30276-1 - DOI - PMC - PubMed
    1. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11-22. 10.1056/NEJMoa052434 - DOI - PubMed
    1. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33. 10.1056/NEJMoa052664 - DOI - PubMed
    1. Rotavirus vaccines WHO position paper: January 2013 - Recommendations. Vaccine. 2013;31(52):6170-1. 10.1016/j.vaccine.2013.05.037 - DOI - PubMed
    1. The Rota Council. Global introduction status. [Accessed: 17 Jun 2022]. Available from: https://preventrotavirus.org/vaccine-introduction/global-introduction-st...

Publication types

Substances

LinkOut - more resources